PAHC Phibro Animal Health Corporation
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, copper, manganese, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for use in personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 1946 and is headquartered in Teaneck, New Jersey.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Phibro Animal Health (NASDAQ: PAHC)
›
Phibro Animal Health (NASDAQ: PAHC) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 2,605 employees.
The shares were at 34.08 USD on 19 November 2026, down 16.8% over 52 weeks. Its 52-week range is 28.25 USD to 60.08 USD: the price is 43.3% below the high and 20.6% above the low.
At a market capitalisation of 1.38B USD, it trades at 13.6 times trailing earnings and 8.8 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a discount of 45% for PAHC. It pays a dividend yielding 1.35% (it pays out 19% of its earnings), against a median of 1.90% among the dividend payers in that peer group.
Phibro Animal Health reports return on equity of 25.9%, an operating margin of 12.7% and revenue up 6.3% year over year.
Its debt exceeds its cash by 706.39M USD, a debt-to-equity ratio of 2.05. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 3 analysts cover the stock, with an average rating of Hold; their mean price target of 47.00 USD is 37.9% above the current price. The next earnings report is expected on 3 February 2027.